Please login to the form below

Not currently logged in
Email:
Password:

NICE revises Victoza recommendation

NICE has released a revised preliminary recommendation for Novo Nordisk's Victoza (liraglutide) for patients with type 2 diabetes

The National Institute for Health and Clinical Excellence (NICE) has released a revised preliminary recommendation on the use of Novo Nordisk's once-daily injectable human GLP-1 analogue Victoza (liraglutide) for patients with type 2 diabetes. The revised recommendation maintains the positioning issued in February 2010 and includes the recommendation that Victoza is a clinically and cost-effective treatment option under certain circumstances. 

These circumstances are that liraglutide 1.2mg daily is used in combination with one oral anti-diabetic tablet (metformin or a sulphonylurea) for treatment in patients with type 2 diabetes, if:

• they are intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and

• they are intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.

The release of the revised recommendation follows a second appraisal committee meeting held in April, and final guidance is expected by October this year. Novo Nordisk will continue dialogue with NICE regarding patient groups that could benefit from liraglutide 1.8mg and to support the use of liraglutide in line with the licence it was granted in June 2009 by the European Medicines Agency (EMA, formerly EMEA).

14th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics